Therapeutic modality |
Mode of action and Remarks |
Glucocorticoids |
Increase hepatic gluconeogenesis and peripheral insulin resistance
Decrease insulin secretion and peripheral glucose utilization |
Diazoxide, Streptozotocin |
Reduce insulin secretion by direct beta cell toxicity |
Somatostatin analogues |
Actions mediated through somatostatin receptors
Not as effective in malignant compared to benign tumours |
Interferon |
Induces cytotoxic lymphocyte mediated beta cell damage |
Evorolimus (mTOR inhibitor) |
? Inhibits insulinĀ secretion
? Induces insulin resistance
? anti tumour growth effects |
Sunitinib (Tyrosine kniase inhibitor) |
Inhibits vascualr endothelial growth factor and platelet drived growth factor receptors |
Radionuclides [19] |
Used mainly in unresectable somatostatin receptor positive tumours |